Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-380228
Filing Date
2026-09-02
Accepted
2026-09-02 16:21:11
Documents
72
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atto-20260630.htm   iXBRL 10-Q 3187582
2 EX-31.1 atto-ex31_1.htm EX-31.1 16199
3 EX-31.2 atto-ex31_2.htm EX-31.2 16229
4 EX-32.1 atto-ex32_1.htm EX-32.1 8989
5 EX-32.2 atto-ex32_2.htm EX-32.2 9019
  Complete submission text file 0001193125-26-380228.txt   10455793

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atto-20260630.xsd EX-101.SCH 1087814
76 EXTRACTED XBRL INSTANCE DOCUMENT atto-20260630_htm.xml XML 1810029
Mailing Address 1091 INDUSTRIAL ROAD SAN CARLOS CA 94070
Business Address 1091 INDUSTRIAL ROAD SAN CARLOS CA 94070 5103995001
Attovia Therapeutics, Inc. (Filer) CIK: 0002058707 (see all company filings)

EIN.: 921510574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43423 | Film No.: 261355104
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)